GSTM1 and chronic kidney disease: The present simulation modeling, employed to examine the cost-effectiveness of recommended anemia treatment targets, indicates that among persons with CKD stage 3–4 both Hb targets of 10 g/dl and 10.5 g/dl are cost effective, and the latter may be the most cost-effective.